A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol
SJ Pascoe, DA Lipson, N Locantore… - European …, 2016 - Eur Respiratory Soc
Patients with symptomatic advanced chronic obstructive pulmonary disease (COPD) who
experience recurrent exacerbations are particularly at risk of poor outcomes and present a …
experience recurrent exacerbations are particularly at risk of poor outcomes and present a …
Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
DMG Halpin, R Birk, N Brealey, GJ Criner… - ERJ open …, 2018 - Eur Respiratory Soc
Triple inhaled corticosteroid (ICS)/long-acting muscarinic antagonist (LAMA)/long-acting β2-
agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive …
agonist (LABA) therapy is recommended for symptomatic patients with chronic obstructive …
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized …
GT Ferguson, N Brown, C Compton, TC Corbridge… - Respiratory …, 2020 - Springer
Background The comparative efficacy of inhaled corticosteroid/long-acting muscarinic
antagonist/long-acting β 2-agonist (ICS/LAMA/LABA) triple therapy administered via single …
antagonist/long-acting β 2-agonist (ICS/LAMA/LABA) triple therapy administered via single …
The IMPACT study–single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: efficacy and safety in a Japanese population
M Kato, K Tomii, K Hashimoto, Y Nezu… - … Journal of Chronic …, 2019 - Taylor & Francis
Purpose The Informing the Pathway of COPD Treatment (IMPACT) study demonstrated that
single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) …
single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) …
Triple therapy trials in COPD: a precision medicine opportunity
S Suissa, A Ariel - European Respiratory Journal, 2018 - Eur Respiratory Soc
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy document for the
treatment of chronic obstructive pulmonary disease (COPD) suggests that, after …
treatment of chronic obstructive pulmonary disease (COPD) suggests that, after …
Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy compared with other therapies for the treatment of COPD: a network meta-analysis
AS Ismaila, K Haeussler, A Czira, JH Youn… - Advances in …, 2022 - Springer
Abstract Introduction Randomized controlled trials (RCTs) comparing triple therapies
(inhaled corticosteroid [ICS], long-acting β2-agonist [LABA], and long-acting muscarinic …
(inhaled corticosteroid [ICS], long-acting β2-agonist [LABA], and long-acting muscarinic …
Cost-effectiveness analysis of a once-daily single-inhaler triple therapy for patients with chronic obstructive pulmonary disease (COPD) using the FULFIL trial: a …
M Schroeder, N Benjamin, L Atienza… - … Journal of Chronic …, 2020 - Taylor & Francis
Purpose To evaluate the cost-effectiveness of once-daily fluticasone furoate/umeclidinium/
vilanterol (FF/UMEC/VI) vs twice-daily budesonide/formoterol (BUD/FOR) in patients with …
vilanterol (FF/UMEC/VI) vs twice-daily budesonide/formoterol (BUD/FOR) in patients with …
Efficacy and safety of budesonide/glycopyrronium/formoterol fumarate versus other triple combinations in COPD: a systematic literature review and network meta …
A Bourdin, N Molinari, GT Ferguson, B Singh… - Advances in …, 2021 - Springer
In patients with chronic obstructive pulmonary disease (COPD) who experience further
exacerbations or symptoms, despite being prescribed dual long-acting muscarinic …
exacerbations or symptoms, despite being prescribed dual long-acting muscarinic …
Clinical concepts for triple therapy use in patients with COPD: a Delphi consensus
M Miravitlles, S Acharya, B Aggarwal… - … Journal of Chronic …, 2023 - Taylor & Francis
Purpose Role of triple therapy in chronic obstructive pulmonary disease (COPD)
management is supported by growing evidence, but consensus is lacking on various …
management is supported by growing evidence, but consensus is lacking on various …
Comparing the efficacy and safety profile of triple fixed-dose combinations in COPD: a meta-analysis and IBiS score
P Rogliani, J Ora, F Cavalli, M Cazzola… - Journal of clinical …, 2022 - mdpi.com
Background: Triple fixed-dose combination (FDC) therapy is recommended in severe
chronic obstructive pulmonary disease (COPD) patients experiencing frequent …
chronic obstructive pulmonary disease (COPD) patients experiencing frequent …